June 06, 2013
Teva Pharmaceuticals Industries Ltd. on Wednesday agreed to a settlement with Bristol-Myers Squibb Co. and Merck Sharp & Dohme Corp., ending claims in New York federal court that its planned generic version of HIV treatment Atripla had infringed two patents.